(Q33851320)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

5

Claus Belka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

4

Stephanie E. Combs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Maximilian Niyazi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Maya Flieger

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

3 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma

19 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Post-radiation increase in VEGF enhances glioma cell motility in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

MiRNA expression patterns predict survival in glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Bevacizumab and daily temozolomide for recurrent glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Therapeutic options for recurrent malignant glioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Scale to predict survival after surgery for recurrent glioblastoma multiforme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Angiogenesis in brain tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083332

FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Hypofractionated reirradiation for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Irradiation and bevacizumab in high-grade glioma retreatment settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1748-717X-9-128

Bevacizumab: current indications and future development for management of solid tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24893775

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1748-717X-9-128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

19 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

PubMed publication ID

24893775

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24893775%20AND%20SRC:MED&resulttype=core&format=json